TITLE

Primary Adenocarcinoma of the Urinary Bladder

AUTHOR(S)
Kapur, Payal; Lotan, Yair; King, Ellen; Kabbani, Wareef; Mitra, Anirban P.; Mosbah, Ahmed; Abol-Enein, Hassan; Ghoneim, Mohamed; Youssef, Ramy F.
PUB. DATE
June 2011
SOURCE
American Journal of Clinical Pathology;Jun2011, Vol. 135 Issue 6, p822
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Primary adenocarcinomas of the urinary bladder are uncommon, and the molecular pathways are currently not well defined. In this study, we assessed the association between biologic markers and clinicopathologic characteristics in a cohort of 21 patients with primary urinary bladder adenocarcinoma. Immunohistochemical staining for cell cycle-specific markers, including p53, p21, p27, Ki-67, and cyclin E, were performed on sections of a tissue microarray construct. The tumors were high grade in 12 (57%) and pT2 or higher in 18 (86%); lymph nodes were involved in 6 cases (29%); and there was pathologic evidence of schistosomiasis in 14 (67%). The best prognostic combination of markers was combined alterations in p27 and Ki-67 and was associated with stage (P = .012), grade (P = .005), DNA ploidy (P = .005), and lymph node involvement (P = .04). Stage, lymph node involvement, combined alterations of p27 and Ki-67, and combined alterations of all 5 biomarkers were associated with increased probability of disease recurrence and cancer-specific mortality (P < .05).
ACCESSION #
70108846

 

Related Articles

  • Immunohistochemical Profile for Unknown Primary Adenocarcinoma. Hashimoto, Kenji; Sasajima, Yuko; Ando, Masashi; Yonemori, Kan; Hirakawa, Akihiro; Furuta, Koh; Tsuda, Hitoshi; Fujiwara, Yasuhiro // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Background: Development of tailored treatment based on immunohistochemical profiles (IPs) of tumors for cancers of unknown primary is needed. Methodology/Principal Findings: We developed an algorithm based on primary known adenocarcinoma for testing sensitivity and specificity. Formalin-fixed...

  • Immunohistochemical Profile for Unknown Primary Adenocarcinoma. Hashimoto, Kenji; Sasajima, Yuko; Ando, Masashi; Yonemori, Kan; Hirakawa, Akihiro; Furuta, Koh; Tsuda, Hitoshi; Fujiwara, Yasuhiro // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Background: Development of tailored treatment based on immunohistochemical profiles (IPs) of tumors for cancers of unknown primary is needed. Methodology/Principal Findings: We developed an algorithm based on primary known adenocarcinoma for testing sensitivity and specificity. Formalin-fixed...

  • ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients. Qi, Mei; Yang, Xiaoqing; Zhang, Fan; Lin, Tao; Sun, Xiubin; Li, Yanjiang; Yuan, Huiqing; Ren, Yubo; Zhang, Juan; Qin, Xiaomin; Han, Bo // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homologue (PTEN) deletions and EGFR family aberrations were characterized as potential biomarkers for prostate cancer (PCa) patient management. Although ERG gene rearrangement has been identified in approximately 50% of...

  • Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer. Kang, Byung; Lee, Dakeun; Chung, Ho; Han, Jae; Kim, Young-Bae // Journal of Cancer Research & Clinical Oncology;Nov2013, Vol. 139 Issue 11, p1835 

    Purpose: Tetraspanin CD151 is known to be involved in cancer invasion and metastasis, and its overexpression appears to be associated with a poor prognosis for various types of cancer. However, the expression status of CD151 and its prognostic impact in advanced gastric cancer (AGC) has not yet...

  • Diagnostic and prognostic value of bladder cancer-related transcript markers in urine. Schmidt, Juliane; Propping, Catharina; Siow, Woei-Yun; Lohse-Fischer, Andrea; Toma, Marieta; Baldauf-Twelker, Anka; Hakenberg, Oliver; Wirth, Manfred; Fuessel, Susanne // Journal of Cancer Research & Clinical Oncology;Feb2016, Vol. 142 Issue 2, p401 

    Purpose: Since cytology as the current 'gold standard' for noninvasive detection of bladder cancer (BCa) is characterized by a relatively low sensitivity, urinary transcript levels of survivin (SVV), Ki-67 and cytokeratin 20 (CK20) were evaluated as alternative or complementary biomarkers....

  • Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence. Shore, Neal D.; Fernandez, Cecilia A.; Shuber, Anthony P. // Research & Reports in Urology;2012, Issue 4, p49 

    Background: The purpose of this study was to establish the clinical performance of a urine-based assay, called a multianalyte diagnostic readout, in monitoring for bladder cancer recurrence. Methods: This was a prospective, multicenter, single assessment observational study. The multianalyte...

  • Low RKIP expression associates with poor prognosis in bladder cancer patients. Afonso, Julieta; Longatto-Filho, Adhemar; Martinho, Olga; Lobo, Francisco; Amaro, Teresina; Reis, Rui; Santos, LĂșcio // Virchows Archiv;Apr2013, Vol. 462 Issue 4, p445 

    Urothelial bladder cancer (UBC) is a heterogeneous type of disease. It is urgent to screen biomarkers of tumour aggressiveness in order to clarify the clinical behaviour and to personalize therapy in UBC patients. Raf kinase inhibitory protein (RKIP) is a metastasis suppressor, and its...

  • Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer. Lance P. Walsh; Yair Lotan // Laboratory Medicine;Jul2006, Vol. 37 Issue 7, p429 

    The most important tools for making therapeutic decisions include stage and grade for bladder and kidney cancer, as well as PSA for prostate cancer. Unfortunately, all tumors of the same stage and grade do not behave the same, indicating the need for additional markers that can provide more...

  • Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer. Yang, Yongmei; Qu, Ailin; Liu, Jingkang; Wang, Rui; Liu, Yingjie; Li, Gang; Duan, Weili; Fang, Qian; Jiang, Xiumei; Wang, Lili; Zheng, Guixi; Du, Lutao; Zhang, Xin; Wang, Chuanxin // PLoS ONE;8/7/2015, Vol. 10 Issue 8, p1 

    MiR-210 is the master hypoxamir that generally exhibits oncogenic properties in most human solid tumors including bladder cancer (BC). However, it remains unknown about the clinical significance of circulating miR-210 levels in BC. In this study, we found that serum miR-210 was up-regulated in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics